MBX Biosciences (MBX) Share-based Compensation (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Share-based Compensation data on file, last reported at $40.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 2113.16% year-over-year to $40.7 million; the trailing twelve-month figure through Mar 2026 stood at $40.7 million (up 872.75% YoY), and the FY2025 full-year result was $25.2 million, up 41.57% from the prior year.
• Share-based Compensation improved to $40.7 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $40.7 million in Q1 2026 to a low of $227000.0 in Q3 2023.
• A 4-year average of $8.6 million and a median of $1.6 million in 2024 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 6637.8% in 2025, while the deepest fall reached 13.31% in 2025.
• Tracing MBX's Share-based Compensation over 4 years: stood at $1.0 million in 2023, then jumped by 46.17% to $1.5 million in 2024, then soared by 78.49% to $2.7 million in 2025, then surged by 1432.38% to $40.7 million in 2026.
• Business Quant data shows MBX's Share-based Compensation at $40.7 million in Q1 2026, $2.7 million in Q4 2025, and $22.3 million in Q3 2025.